Paushak Ltd Q2 FY26 – When the Phosgene King Decides to Throw a Bonus Party While Profits Take a Nap
1. At a Glance
Phosgene. The gas that terrified chemists in textbooks has made Paushak Ltd a ₹1,807 crore market-cap star in the real world. This Vadodara-based Alembic Group gem is India’s largest phosgene-based specialty chemicals manufacturer, and it just wrapped up Q2 FY26 with revenue of ₹58.78 crore and a profit after tax (PAT) of ₹8.61 crore. That’s a 39% profit drop from the same quarter last year, because apparently even toxic gases can catch an economic cold.
But investors barely blinked—why? Because the company threw a triple bonus party: a 3:1 bonus issue and a share split (₹10 → ₹5). That’s like saying, “Sure, profits fell, but hey, here are more shiny shares to distract you.”
At ₹733 per share, Paushak trades at a P/E of 39.7—expensive enough to make the molecules blush. The return over the past year is a modest 12%, but over five years, the stock has quietly compounded at 11%. Meanwhile, ROE sits at 9.76%, ROCE at 11.2%, and OPM hovers around 29%.
The company is now debt-light (Debt/Equity: 0.12), fully unpledged, and still under the old-money umbrella of the Alembic Amin dynasty, one of India’s most seasoned industrial families. So yes, it’s a small-cap company—but with an old-money swagger and a periodic table full of attitude.
2. Introduction
Let’s be honest—most people think “phosgene” and immediately imagine a chemistry lab gone wrong. But for Paushak, phosgene is liquid gold. This company has been quietly converting hazardous gas into high-margin chemistry that feeds pharma, agrochemical, and performance material industries.
While everyone else in specialty chemicals is busy talking about “fluorine chemistry” and “green solvents,” Paushak is that nerd in the corner who says, “Hold my Erlenmeyer flask; I’ve got phosgene.”
The company sits comfortably within the Alembic industrial family tree, sharing DNA with Alembic Pharmaceuticals. It’s like the family’s chemical cousin who took a dangerous subject and turned it into a business model.
Now, Q2 FY26 brought a mixed bag. Sales at ₹58.78 crore grew only 2.56% YoY, but profits crashed nearly 40%. The OPM dropped to 25.18%, its lowest in several quarters, suggesting maybe raw materials or energy costs bit harder than expected.
And yet, Paushak’s management didn’t panic. Instead, they rewarded shareholders with a massive 3:1 bonus and share split, raised the borrowing limit to ₹750 crore (perhaps to fund the next chemistry experiment), and changed their CEO—all in one fiscal quarter.
Who says small-cap chemical companies are boring?
3. Business Model – WTF Do They Even Do?
Paushak is India’s largest phosgene-based specialty chemical manufacturer. For the uninitiated, phosgene is not your friendly gas—it’s lethal in pure form. But controlled properly, it’s a cornerstone intermediate for making compounds like chloroformates, isocyanates, and carbamates, all used in pharmaceuticals, agrochemicals, dyes, plastics, and perfumeries.
So yes, the same compound that terrified soldiers in World War I now helps make your perfume last longer. Irony level: Nobel Prize.
The company has a production capacity of 14,400 MT/year (tripled after FY22 expansion) and even received the “Responsible Care” certification from the Indian Chemical Council—a rare badge for a small firm handling such risky chemistry.
Paushak operates on a B2B model, supplying high-value intermediates to larger chemical and pharma players. It’s not a consumer brand; it’s the chemical whisperer that makes other products possible.
Exports contribute 22% of revenue, while domestic sales form the rest (78%). But given the rising global demand for niche intermediates, export growth could become a bigger story if the company scales smartly.
If this were a Bollywood film, Paushak would be the backstage technician ensuring the superstar chemical companies get their cues right—no limelight, but absolutely essential.
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
58.78
57.31
55.88
2.56%
5.19%
EBITDA (₹ Cr)
14.80
17.03
17.85
-13.1%
-17.1%
PAT (₹ Cr)
8.61
14.20
12.03
-39.4%
-28.4%
EPS (₹)
3.50
5.77
4.89
-39.4%
-28.4%
Annualised EPS = ₹3.50 × 4 = ₹14.0, giving a current P/E of ~52.3x.
That’s a spicy valuation for a company whose profits are slipping faster than lab gloves on a sweaty chemist.
Commentary: Margins have compressed, earnings are down, and yet the market continues to treat Paushak like the teacher’s pet of specialty chemicals. Maybe because investors believe in the long-term story—or maybe because phosgene just sounds intimidating enough to justify a premium.
5. Valuation Discussion – Fair Value Range Only
Let’s run the numbers like a responsible nerd.
Method 1: P/E Approach Annualised EPS = ₹14.0 Industry average P/E ≈ 31.6 → Fair Value Range = ₹14 × (30–35) = ₹420–₹490
Method 2: EV/EBITDA Approach EV = ₹1,866 Cr EBITDA (TTM) = ₹63 Cr EV/EBITDA = 29.6x If we normalize to peer average of 18–22x → Fair EV range = ₹1,134–₹1,386 Cr Subtract debt (₹60 Cr), add cash equivalents ≈ negligible → Fair Equity Value ≈ ₹1,100–₹1,350 Cr With 2.47 Cr shares (pre-bonus), that’s ₹445–₹550/share
Method 3: DCF (Simplified) Assume free cash flow growth of 8%, discount rate 12%, terminal growth 3%. Current FCF roughly ₹25 Cr → Fair Value = ₹500–₹600/share
✅ Fair Value Educational Range: ₹440–₹580 per share (Current price ₹733 → trades above fair range)
Disclaimer: This fair value range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
Q2 FY26 was anything but boring:
3:1 Bonus Issue + Share Split: Announced and executed between August–October 2025. Bonus shares allotted on October 6, increasing paid-up capital to ₹12.33 crore. That’s corporate finance cosplay at its best.
CEO Drama: Longtime CEO Abhijit Joshi resigned on April 2, replaced by Chintan Gosaliya. Either the lab fumes
